Opioid-induced constipation: a multidisciplinary problem.
Opioid-induced constipation: a multidisciplinary problem
Professor Andrew Davies, President of MASCC (Multinational Association of Supportive Care in Cancer) explains the difference between OIC and other types of constipation, presenting quantitative data from the StOIC 1 study, a large study involving cancer patients in the UK, to highlight its impact on patients’ quality of life.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email: PVUK@grunenthalmeds.com
MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here
-
References
1. KKI/INT/MOV/0124 November 2023